Tango Therapeutics Inc. (TNGX)
NASDAQ: TNGX
· Real-Time Price · USD
6.94
-0.28 (-3.88%)
At close: Aug 19, 2025, 3:59 PM
Tango Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Collaboration Revenue Revenue | 29.97M | 31.53M | 24.86M | 26.04M |
| Collaboration Revenue Revenue Growth | -4.94% | +26.82% | -4.54% | n/a |
| License Revenue Revenue | 12.1M | 5M | n/a | 11M |
| License Revenue Revenue Growth | +142.00% | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 11.34M | 11.48M | 11.09M | 11.22M | 10.77M | 10.66M | 9.11M | 9.21M | 9.17M | 8.01M | 7.89M | 8.1M | 7.23M | 6.81M | 6.07M | 4.43M | 3.63M | 3.47M | 3.02M | 2.52M | 2.38M | 1.95M |
| Selling, General, and Administrative Revenue Growth | -1.21% | +3.52% | -1.18% | +4.17% | +1.05% | +17.09% | -1.13% | +0.38% | +14.49% | +1.60% | -2.62% | +11.99% | +6.24% | +12.22% | +36.84% | +22.12% | +4.70% | +14.95% | +19.78% | +5.89% | +21.76% | n/a |
| Research and Development Revenue | 32.18M | 36.44M | 33.94M | 33.26M | 38.65M | 38.06M | 31.34M | 27.15M | 28.67M | 28.04M | 29.09M | 28.74M | 23.74M | 24.33M | 21.63M | 21.92M | 19.08M | 15M | 15.06M | 12.98M | 11.13M | 10.82M |
| Research and Development Revenue Growth | -11.69% | +7.38% | +2.03% | -13.95% | +1.55% | +21.46% | +15.43% | -5.31% | +2.25% | -3.62% | +1.21% | +21.07% | -2.42% | +12.46% | -1.32% | +14.91% | +27.19% | -0.42% | +16.07% | +16.61% | +2.84% | n/a |